Browsing School of Pharmacy and Pharmaceutical Sciences by Subject "MCL-1"
Now showing items 1-1 of 1
-
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
(2018)Background: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to ...